> My guess (based upon personal experience within an entirely different industry), is that biotech management stinks at negotiations just like the technical teams I know. <
Actually Paul Goddard was a senior executive on the other side of partnership discussions when he was at Smithkline, and John Varian is a top notch executive who has handled many negotiations from the sale of Neurex, to the sale of Genset, on very good terms.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.